Kayformin 500 SR Tablet contains Metformin hydrochloride 500 mg as its active ingredient and is formulated as a sustained-release (SR) preparation to provide prolonged glycemic control in patients with type 2 diabetes mellitus. Metformin is a biguanide antihyperglycemic agent that improves glucose tolerance by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and enhancing insulin sensitivity by increasing peripheral glucose uptake and utilization. Kayformin 500 SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, particularly in overweight patients or those for whom diet and exercise alone have proven insufficient. The sustained-release formulation allows for once-daily dosing, which may improve patient compliance and reduce gastrointestinal side effects commonly associated with immediate-release formulations. It is important to monitor renal function prior to and during therapy, as Metformin is contraindicated in patients with significant renal impairment due to the risk of lactic acidosis, a rare but serious metabolic complication. Patients should also be advised regarding potential side effects such as gastrointestinal disturbances, including nausea, vomiting, and diarrhea, which often diminish over time. Kayformin 500 SR should be used under medical supervision with appropriate lifestyle modifications for optimal diabetes management.